Tumor blood flow and systemic shunting in patients receiving intraarterial chemotherapy for head and neck cancer

Harvev A. Ziessman, James H. Thrall, John W. Keyes, Jack E. Juni, Shan R. Baker

Research output: Contribution to journalArticlepeer-review

Abstract

Radionuclide techniques have been used to estimate the systemic shunt and to quantitate blood flow to the tumor and a reference normal tissue in nine patients undergoing intraarterial chemotherapy for head and neck cancer. The systemic shunt was calculated as the percentage of pulmonary trapping of intraarterially injected 99100Tc-labeled macroaggregated albumin. The mean systemic shunt in the 12 separate arteries studied was 23 ± 13% (SE) (range 8-43%). Quantitative blood flow was determined from the slope of the washout curve of intraarterially injected 133Xe. The mean tumor blood flow was 13.6 ± 6.7 ml/100 g/min, while the mean blood flow to the scalp was 4.2 ± 2.1 ml/100 g/min providing a mean tumor/normal tissue ratio of 3.9 ± 2.7. An estimate of blood flow distribution was obtained by calculating the ratio of counts/pixel in the tumor mass versus the remainder of the head as determined by single photon emission computed tomography following an intraarterial injection of 99100Tc-labeled macroaggregated albumin. The mean ratio of tumor to normal tissue perfusion by this technique was 5.6 ± 3.7. These techniques have allowed noninvasive determination of the blood flow parameters associated with intraarterial chemotherapy. At least part of the therapeutic advantage of regional chemotherapy in patients with head and neck cancer is due to a tumor/normal tissue blood flow ratio that favors drug delivery to the tumor contained within the infused volume.

Original languageEnglish (US)
Pages (from-to)4200-4204
Number of pages5
JournalCancer Research
Volume46
Issue number8
StatePublished - Aug 1 1986

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Tumor blood flow and systemic shunting in patients receiving intraarterial chemotherapy for head and neck cancer'. Together they form a unique fingerprint.

Cite this